{"id":"placebo-of-roflumilast","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL193240","moleculeType":"Small molecule","molecularWeight":"403.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo of roflumilast contains no active drug substance and produces no direct pharmacological effect. It is used as a control in clinical trials to compare against the active roflumilast formulation (a phosphodiesterase-4 inhibitor). Any observed effects are attributable to the placebo effect rather than drug action.","oneSentence":"This is a placebo formulation with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:17.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02363335","phase":"PHASE1","title":"The Role of Phosphodiesterase Inhibitors in Incretin Secretion","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2015-02-13","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT00242307","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05-01","conditions":"Bronchial Asthma","enrollment":450},{"nctId":"NCT04636814","phase":"PHASE3","title":"A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-07-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3973},{"nctId":"NCT07314242","phase":"PHASE2","title":"A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD","status":"NOT_YET_RECRUITING","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2026-01-01","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":120},{"nctId":"NCT07297602","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study","status":"RECRUITING","sponsor":"Nora Mohamed Abdelrazik","startDate":"2025-11-20","conditions":"Atopic Dermatitis","enrollment":36},{"nctId":"NCT05418049","phase":"PHASE2","title":"Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-09-08","conditions":"Fragile X Syndrome","enrollment":45},{"nctId":"NCT07233291","phase":"PHASE2","title":"A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults","status":"RECRUITING","sponsor":"Ahmed Ibrahim","startDate":"2025-08-20","conditions":"Psoriasis (PsO)","enrollment":36},{"nctId":"NCT06631170","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-21","conditions":"Atopic Dermatitis (AD)","enrollment":354},{"nctId":"NCT04751071","phase":"PHASE1, PHASE2","title":"The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-02-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT06457191","phase":"PHASE1","title":"Roflumilast and TMS Motor Plasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2024-11-06","conditions":"Other Conditions of Brain","enrollment":20},{"nctId":"NCT06860958","phase":"PHASE3","title":"Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-03-01","conditions":"Depressive Disorder, Major","enrollment":60},{"nctId":"NCT05684484","phase":"PHASE4","title":"Role of Roflumilast in Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-02-01","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT04322929","phase":"PHASE2","title":"Roflumilast in Non-CF Bronchiectasis Study (2019)","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-11-12","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":42},{"nctId":"NCT06643221","phase":"EARLY_PHASE1","title":"Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2018-01-24","conditions":"Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion","enrollment":100},{"nctId":"NCT05763082","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2023-02-07","conditions":"Plaque Psoriasis","enrollment":414},{"nctId":"NCT04854811","phase":"PHASE2","title":"Roflumilast to Treat Cognitive Sequela After Stroke","status":"COMPLETED","sponsor":"Maastricht University","startDate":"2021-07-07","conditions":"Cerebrovascular Disorders, Memory, Functional Recovery","enrollment":100},{"nctId":"NCT05682859","phase":"PHASE4","title":"Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)","status":"RECRUITING","sponsor":"Jacob Pontoppidan Thyssen","startDate":"2023-09-25","conditions":"Chronic Hand Eczema","enrollment":40},{"nctId":"NCT04108377","phase":"PHASE1","title":"Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2019-01-21","conditions":"Asthma","enrollment":5},{"nctId":"NCT04091646","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-04","conditions":"Seborrheic Dermatitis","enrollment":226},{"nctId":"NCT04549870","phase":"PHASE2","title":"Efficacy of Roflumilast in the Treatment of Psoriasis","status":"COMPLETED","sponsor":"Bispebjerg Hospital","startDate":"2021-01-01","conditions":"Psoriasis","enrollment":46},{"nctId":"NCT05884281","phase":"PHASE1, PHASE2","title":"Efficacy of Roflumilast in Prevention of Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-07","conditions":"Peripheral Neuropathy","enrollment":60},{"nctId":"NCT04211389","phase":"PHASE3","title":"Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-17","conditions":"Chronic Plaque Psoriasis","enrollment":442},{"nctId":"NCT04128007","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-01-13","conditions":"Plaque Psoriasis","enrollment":304},{"nctId":"NCT03532490","phase":"PHASE2","title":"Trial of Roflumilast in Asthma Management (TRIM)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-08-03","conditions":"Asthma, Obesity","enrollment":38},{"nctId":"NCT04658654","phase":"PHASE2","title":"Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2021-11-19","conditions":"Mild Cognitive Impairment, Mild Dementia, Amnestic Mild Cognitive Disorder","enrollment":81},{"nctId":"NCT04800172","phase":"PHASE3","title":"The Possible Effects of Roflumilast on Obesity Related Disorders","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-05-01","conditions":"Obesity, PreDiabetes","enrollment":66},{"nctId":"NCT04744090","phase":"PHASE2","title":"Roflumilast as add-on Therapy in Early Cases of ARDS","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-03-21","conditions":"Respiratory Distress Syndrome, Adult","enrollment":76},{"nctId":"NCT04369547","phase":"PHASE1","title":"Roflumilast TMS-EEG Plasticity","status":"WITHDRAWN","sponsor":"University of Calgary","startDate":"2022-01","conditions":"Synaptic Plasticity","enrollment":""},{"nctId":"NCT04755946","phase":"PHASE3","title":"Possible Role of Roflumilast in Diabetic Nephropathy","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2021-03-10","conditions":"Diabetic Nephropathies","enrollment":48},{"nctId":"NCT01973998","phase":"PHASE3","title":"Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization","status":"COMPLETED","sponsor":"Temple University","startDate":"2013-11","conditions":"COPD","enrollment":68},{"nctId":"NCT03988816","phase":"PHASE2","title":"Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2019-12-06","conditions":"Bronchiectasis Adult","enrollment":30},{"nctId":"NCT01433666","phase":"PHASE2","title":"Roflumilast and Cognition","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-09","conditions":"Dementia","enrollment":22},{"nctId":"NCT01509677","phase":"PHASE3","title":"Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-02-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT04122547","phase":"PHASE3","title":"Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2015-01","conditions":"Exacerbation Copd, Bronchiectasis, Lung Function Decreased","enrollment":40},{"nctId":"NCT03428334","phase":"PHASE2","title":"Roflumilast in Non-CF Bronchiectasis Study","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2018-05-10","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":20},{"nctId":"NCT02671942","phase":"PHASE2","title":"A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2016-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":55},{"nctId":"NCT01630200","phase":"PHASE4","title":"Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease and Allied Conditions","enrollment":80},{"nctId":"NCT02451540","phase":"PHASE2","title":"Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging","status":"TERMINATED","sponsor":"FLUIDDA nv","startDate":"2015-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":13},{"nctId":"NCT02097992","phase":"PHASE1, PHASE2","title":"Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD","status":"COMPLETED","sponsor":"University of Miami","startDate":"2013-02","conditions":"COPD","enrollment":11},{"nctId":"NCT03073798","phase":"PHASE4","title":"The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2013-03-18","conditions":"COPD, Chronic Bronchitis, Emphysema","enrollment":12},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01443845","phase":"PHASE4","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-30","conditions":"COPD, COPD Exacerbation, Lung Diseases","enrollment":2354},{"nctId":"NCT01730404","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-10","conditions":"COPD","enrollment":55},{"nctId":"NCT01473758","phase":"PHASE2","title":"Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-02","conditions":"Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation","enrollment":81},{"nctId":"NCT01313494","phase":"PHASE3","title":"A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-03","conditions":"COPD","enrollment":626},{"nctId":"NCT01765192","phase":"PHASE2","title":"Roflumilast Plus Montelukast in Adults With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Asthma","enrollment":64},{"nctId":"NCT02051335","phase":"PHASE1","title":"Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01","conditions":"Memory Impairment, Alzheimer's Disease","enrollment":27},{"nctId":"NCT01703260","phase":"PHASE2","title":"Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-06","conditions":"Nonalcoholic Steatohapatitis","enrollment":20},{"nctId":"NCT01664624","phase":"PHASE1","title":"Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":40},{"nctId":"NCT00297102","phase":"PHASE3","title":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1523},{"nctId":"NCT00313209","phase":"PHASE3","title":"Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":933},{"nctId":"NCT01329029","phase":"PHASE4","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1945},{"nctId":"NCT00424268","phase":"PHASE3","title":"Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":743},{"nctId":"NCT00746434","phase":"PHASE2","title":"A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Plaque Psoriasis","enrollment":""},{"nctId":"NCT00076076","phase":"PHASE3","title":"The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-12","conditions":"Asthma","enrollment":822},{"nctId":"NCT00163527","phase":"PHASE3","title":"Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Asthma","enrollment":2054},{"nctId":"NCT00242320","phase":"PHASE3","title":"Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-08","conditions":"COPD","enrollment":551},{"nctId":"NCT00076089","phase":"PHASE3","title":"OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-12","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":1100},{"nctId":"NCT00746382","phase":"PHASE2","title":"A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Dermatitis","enrollment":""},{"nctId":"NCT00430729","phase":"PHASE3","title":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-01","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":1100},{"nctId":"NCT00062582","phase":"PHASE3","title":"Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":1000},{"nctId":"NCT00297115","phase":"PHASE3","title":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1568},{"nctId":"NCT00108823","phase":"PHASE3","title":"The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-10","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":550},{"nctId":"NCT01140542","phase":"PHASE2","title":"Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-08","conditions":"Diabetes Mellitus Type 2","enrollment":487},{"nctId":"NCT00242294","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":570},{"nctId":"NCT00073177","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Asthma","enrollment":819},{"nctId":"NCT01365533","phase":"PHASE2","title":"A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Allergic Asthma","enrollment":48},{"nctId":"NCT02079844","phase":"PHASE1","title":"Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03","conditions":"Schizophrenia","enrollment":20},{"nctId":"NCT01830959","phase":"PHASE4","title":"Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2013-04","conditions":"Sarcoidosis","enrollment":50},{"nctId":"NCT01572948","phase":"NA","title":"A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2012-06","conditions":"COPD","enrollment":27},{"nctId":"NCT01701934","phase":"PHASE2","title":"Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Laval University","startDate":"2013-02","conditions":"Chronic Obstructive Pulmonary Disease, Metabolic Syndrome","enrollment":14},{"nctId":"NCT01480661","phase":"PHASE4","title":"Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"FLUIDDA nv","startDate":"2011-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":41},{"nctId":"NCT01595750","phase":"PHASE4","title":"Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Spanish Research Center for Respiratory Diseases","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"Placebo of Roflumilast","genericName":"Placebo of Roflumilast","companyName":"FLUIDDA nv","companyId":"fluidda-nv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}